JPRN-jRCT2031220448招募中2 期
Phase II study of nab-paclitaxel plus ramucirumab in combination with nivolumab in unresectable advanced or recurrent gastric cancer after progression to first-line therapy including fluoropyrimidine, platinum, and anti-PD-1/PD-L1 antibody. - PADDLE
Shoji Hirokazu0 个研究点目标入组 45 人开始时间: 2022年11月17日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 发起方
- 入组人数
- 45
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 18age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Histologically diagnosed as adenocarcinoma, signet ring cell carcinoma, or mucinous carcinoma.
- •2.Unresectable advanced or recurrent gastric cancer.
- •3.No severe ascites on CT imaging that extends beyond the pelvic cavity to the upper abdomen. No massive ascites or pleural effusion requiring drainage.
- •4.The patient is capable of oral intake.
- •5.Age at the time of consent is 18 years or older.
- •6.ECOG-PS:0-1.
- •7.Have at least one measurable lesion on contrast-enhanced CT within 28 days prior to enrollment.
- •8.Refractory to combination therapy including pyrimidine fluoride, platinum, and anti-PD-1/PD-L1 antibody or intolerant to drugs other than anti-PD-1/PD-L1 antibody for unresectable advanced or recurrent gastric cancer with one prior regimen.
- •9.Laboratory tests performed within 14 days prior to enrollment meet the criteria. However, the patient must not have received granulocyte colony stimulating factor (G-CSF product) administration or blood transfusion within 14 days prior to blood collection.
- •10.For female of childbearing potential, have agreed to dual contraception, prohibition of egg donation and prohibition of breast feeding from the time of consent until at least 6 months after the last dose of any investigational drug. For male, have agreed to dual contraception and prohibition of sperm donation from the start of investigational drug administration until at least 6 months after the last dose of any investigational drugs.
- •11.Able to provide peripheral venous blood and urine samples for biomarker studies.
- •12.Written consent to participate in the study has been obtained from the patient.
排除标准
- •1.The patient has an active overlapping cancer.
- •2.Clear metastasis to the central nervous system by contrast-enhanced CT or MRI within 28 days prior to enrollment.
- •3.Active infection requiring systemic treatment.
- •4.Pregnant, possibly pregnant, or lactating women.
- •5.Positive for HIV antibody, HBs antigen, or HCV antibody.
- •6.HBs antigen negative, HBs or HBc antibody positive, and HBV-DNA quantification positive.
- •7.Complicated interstitial lung disease, pneumonitis, pulmonary fibrosis, or a history of these diseases.
- •8.Grade 3 or higher (CTCAEv5.0) immune-related adverse events related to previous PD-1/PD-L1 antibody therapy or immune-related adverse events leading to permanent discontinuation of anti-PD-1/PD-L1 antibody.
- •9.Patient has a defined pre-existing or concomitant disease.
- •10.Prior therapy with angiogenesis inhibitors or taxanes.
- •11.Prior therapy with other T-cell-regulating agents except for initial chemotherapy with anti-PD-1 or anti-CTLA-4 antibodies for unresectable advanced or recurrent gastric cancer.
- •12.Have hypertension that is poorly controlled by standard medical management.
- •13.Receiving systemic corticosteroids or immunosuppressive drugs within 14 days prior to enrollment.
- •14.Receiving systemic antineoplastic therapy within 7 days prior to enrollment.
- •15.Receiving radiation therapy within 28 days prior to registration. However, in the case of irradiation for bone metastases, irradiation was performed within 14 days prior to enrollment in the study.
- •16.Received live or attenuated attenuated vaccine within 28 days prior to enrollment.
- •17.Has a history of organ transplantation, including hematopoietic stem cell transplantation.
- •18.Has a history of severe hypersensitivity to nivolumab, ramucirumab, nab-paclitaxel, paclitaxel, or albumin.
- •19. Patient has psychosis or psychiatric symptoms that interfere with daily life and make participation in the study difficult.
研究者
相似试验
已完成
2 期
Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501)gastric cancerJPRN-jRCTs021180016Ishioka Chikashi30
未知
不适用
Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501)gastric cancerJPRN-UMIN000021728Tohoku Clinical Oncology Research and Education Society (T-CORE)30
招募中
2 期
A trial of ramucirumab plus paclitaxel combined therapy for elderly gastric cancer patientsrefractory to first-line treatmentAdvanced gastric cancer, Second-line treatment, Elderly gastric cancerJPRN-jRCT1031200158Kunisaki Chikara35
招募中
2 期
Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancerRefractory small-cell lung cancerJPRN-UMIN000015565Dokkyo Medical University22
已完成
1 期
Phase1/2 study of nab-Paclitaxel + trastuzumab therapy in 2nd line treatment for HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab combined with fluoropyrimidine and platinum.HER2-positive gastric cancerJPRN-UMIN000014873Kyoto Prefectural University of Medicine, Gatroenterology and Hepatology23